Steinberg Quoted on US Supreme Court’s Dismissal of Challenge to FDA’s Mifepristone Regulation
Bloomberg Law
Health Care Partner Jill A. Steinberg was quoted by Bloomberg Law on the expected difficulties in finding associational standing following the US Supreme Court’s dismissal of a challenge regarding standing against the US Food and Drug Administration’s (FDA) attempts to regulate the drug Mifepristone, commonly used in abortion procedures.
The decision has sparked a broader conversation in the legal community about the future of associational standing, particularly in health and life sciences lawsuits. This ruling has led to an expectation of more rigorous scrutiny of claims made by business associations alleging harm.
In reference to the increased scrutiny of health-care-related lawsuits, particularly those involving contentious issues like Mifepristone regulation or drug pricing after the Court’s decision, “It’s going to be an even more in depth review in order to find associational standing,” said Jill.
Read the full article here.
Contacts
- Related Industries